This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain acyclic diamines, which are agonists of TRPV4 channel receptors.
[EN] ACYCLIC 1,4-DIAMINES AND USES THEREOF<br/>[FR] 1,4-DIAMINES ACYCLIQUES ET LEURS UTILISATIONS
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2007030761A2
公开(公告)日:2007-03-15
[EN] This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain acyclic diamines, which are agonists of TRPV4 channel receptors. [FR] L'invention concerne de nouveaux composés utiles dans le traitement de maladies associées au récepteur canal TRPV4. L'invention concerne plus particulièrement certaines diamines acycliques agonistes des récepteurs canaux TRPV4.
[EN] CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA RIBONUCLÉOTIDE RÉDUCTASE (RNR) DE SULFONAMIDE CYCLIQUE ET LEURS UTILISATIONS
申请人:[en]BOUNDLESS BIO, INC.
公开号:WO2023043923A1
公开(公告)日:2023-03-23
Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a cyclic sulfonamide RNR inhibitor disclosed herein.
Ammonium formate-based one-pot reductive Heck reactions for the construction of cyclic sulfonamides
A modified method is reported for the conversion of unsaturated sulfonamides into their cyclic saturated counterparts. This method utilises a single palladium catalyst for an intramolecular Heck reaction and subsequent transferhydrogenation, which is achieved in one-pot following the addition of ammoniumformate. Accordingly, a range of fourteen structural variations are reported and under optimal